Comparison of Therapeutic Outcomes: Two Triple-Therapy Approaches for H. pylori Eradication in Gastric Ulcer Disease

Abstract

Gastric ulcer is a prevalent digestive disease, primarily caused by Helicobacter pylori infection. H. pylori infection poses a substantial challenge for medical practitioners due to increased antibiotic resistance. Objectives: To compare the efficacy of a 14-days clarithromycin-based triple therapy (TRT) with a moxifloxacin-based TRT for eradicating Helicobacter pylori in gastric ulcer disease. Methods: A quasi experimental study was conducted with 294 positive H. pylori patients divided into two groups. Group A was given standard triple therapy while Group B received moxifloxacin-based triple therapy. Data collection commenced after obtaining IRB approval and informed consent from all participants. Descriptive statistics was used to calculate frequency and percentages. Differences between the two groups were compared using the fisher exact analysis at a significance level, p-value < 0.05. Results: In the group with standard triple therapy (TRT), the eradication rates of H. pylori were reported as 67.3 % intention-to-treat (ITT) and 76.1% per-protocol (PP) analysis. In contrast, in the moxifloxacin-based triple therapy (MAO) group, the eradication rates were 86.3% ITT and 92.7% PP analysis. The eradication rates with moxifloxacin-containing triple therapy were statistically significant than standard TRT (p = 0.001). Furthermore, few side effects were evident in the moxifloxacin TRT group (p < 0.001) compared to the standard TRT group. Conclusions: In Pakistan, moxifloxacin-containing triple therapy may offer a notably superior treatment option for eradicating H. pylori infection compared to standard triple therapy.